

**13th John Vane Memorial Symposium
on Prostacyclin Science and
Pulmonary Vascular Disease**
16-17 March 2018



Foreword by Professor Chris Thiernemann, FMedSci



Dear Friends and Colleagues,

It is my great pleasure to welcome you to the 13th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease at The Royal Society. Thank you once again to United Therapeutics for their continued support of the series via their provision of an unrestricted educational grant.

Since the inception of the series in 2006, we have strived to update you on the very latest research and clinical advances in PAH. The programme of the 13th JVMS includes a wide variety of important topics ranging from pathophysiology to risk assessment, prognosis, guideline implementation and patient stratification in patients with PAH to regulatory aspects relating to the registration of orphan drugs in PAH.

We look forward to hearing your thoughts on this year's presentations as well as learning about your personal experiences of working in this area. We are always open to receiving your suggestions of topics you would like to see included in future JVMS (2019-2021).

In the meantime, I and the rest of the organising team wish you a useful and enjoyable few days here at the Royal Society!

With warm regards,

Chris

Professor Chris Thiernemann, MD PhD FBPhS FRCP FMedSci

Contact: c.thiernemann@qmul.ac.uk

Sir John Vane, FRS, Nobel Laureate

“It is sometimes said that the major discoveries have already been made and that there is nothing important left to find. This attitude is altogether too pessimistic. There are plenty of things left to discover. The trick is to find the right path from one to other.”

John Vane



16 March 2018

8.45-9.45am Registration, tea and coffee

9.45am Welcome
Chris Thiemermann, Queen Mary University of London, London, UK

Session I

Chairs: **Chris Thiemermann, Queen Mary University of London, UK**
Dario Vizza, La Sapienza University of Rome, Rome, Italy

10.00am Drug Development in Pulmonary Arterial Hypertension and the Orphan Drugs Regulation in Europe
Bruno Sepodes, University of Lisbon, Lisbon, Portugal

10.30am Refreshments

Session II

Chairs: **Brendan Whittle, Queen Mary University of London, UK**
Meinhard Kneussl, University of Vienna, Vienna, Austria

11.00am Three years experience with Oral Prostanoids: What have we learned?
Jim White, University of Rochester Medical Centre, New York, USA

11.30am Similarities and differences of IP-agonists and Prostanoids : The Basic Science Perspective
Lucie Clapp, University College London, London, UK

12.00pm Similarities and differences of IP-agonists and Prostanoids: The Clinical Perspective
Dario Vizza, La Sapienza University of Rome, Rome, Italy

12.30pm Lunch

Session III

Chairs: **Paul Corris, Newcastle University, Newcastle, UK**
Jim White, University of Rochester Medical Centre, New York, USA

2.00pm Novel Aspects of the Pathophysiology of Pulmonary Hypertension
Marlene Rabinovitch, Stanford University, Stanford, USA

2.30pm Is there still enough evidence for Parenteral treatments in PH?
Irene Lang, Medical University of Vienna, Austria

3.00pm Is there a role for PRN inhaled Prostanoid-use to increase Exercise Capacity in PH?
Adaani Frost, Weill Cornell Medicine College, Houston, USA

3.30pm Refreshments

Session IV

Chairs: **Robert Naeije, Universite Libre de Bruxelles, Belgium**
Irene Lang, University of Vienna, Vienna, Austria

4.00pm Advances in determination of RV function in Pulmonary Hypertension by CMR imaging
Andrew Peacock, University of Glasgow, UK

4.30pm Exercise-induced PH: Treat or Don't treat?
David Systrom, Brigham and Women's Hospital, Boston, USA

5.00-6.30pm Meeting adjournment and Evening Reception at the Royal Society

17 March 2018

8.00am Tea and coffee

Session V

Chairs: **Andrew Peacock, University of Glasgow, UK**
Marc Humbert, Université Paris-Sud, Paris, France

9.00am Risk Assessment, Prognosis and Guideline Implementation in PAH
Olivier Sitbon, Université Paris-Sud, Paris, France

9.30am Management of WHO Group II PH due to Cardiac Diseases
Robert Naeije, Universite Libre de Bruxelles, Belgium

10.00am Management of WHO Group III PH due to Chronic Lung Disorders
Rajeev Sagar, University of Arizona, Phoenix, USA

10.30am Refreshments

Session VI

Chair: **Olivier Sitbon, Université Paris-Sud, Paris, France**
Marlene Rabinovitch, Stanford University, Stanford, USA

11.00pm Clinical phenotypes and survival of Pre-capillary Pulmonary Hypertension in Systemic Sclerosis
Marc Humbert, Université Paris-Sud, Paris, France

11.30pm Heart Failure with Preserved Ejection Fraction: Clinical study design and treatment
Mardi Gomberg-Maitland, Inova Fairfax Heart and Vascular Institute, Falls Church, USA

12.00pm Translation of Stratified Medicine for PAH into practice
Paul Corris, Newcastle University, Newcastle, UK

12.30pm Progress towards a Molecular Stratification of PAH
Martin Wilkins, Imperial College, London, UK

1.00pm Lunch

2.00pm Close of meeting

John Vane Memorial Symposium 2017

The 12th John Vane Memorial Symposium drew both new and returnee' speakers and delegates to The Royal Society in London from 25 different countries; providing them with a forum to meet with colleagues and friends and discuss the very latest developments in PAH.

In addition to the many high-calibre presentations, which explored the latest thinking in the pathophysiology and treatment of the condition, the debate entitled "The PAH Patient" was extremely well received. We would like to thank all of the contributors and, indeed, all of the speakers for their greatly valued participation.

Professor Chris Thiemermann, CEO of William Harvey Research Limited and Faculty Chair of the John Vane Memorial Symposium said *"It is always my great pleasure to work alongside friends and colleagues on this symposia series. The 12th symposium built on the success of previous years and delivered yet another valuable opportunity to learn about and discuss the very latest topics in PAH. We hope that by sharing the latest advances in treatment and by debating their experience with patients, nurses and doctors, we will ultimately improve both the clinical outcome and the quality of life of our patients"*.

Please see a selection of images from the 2017 symposium which we hope you will enjoy.



2017 Speaker faculty



Members of the 2017 delegation



Engaged participants



Friends and colleagues



Professor Paul Corris



Patient debate participants

William Harvey Research® Limited

Contract Research

WHRL has been leading the way as a contract research organisation (CRO) for the biotech and pharmaceutical sectors for over 20 years, both nationally and internationally. It offers a preclinical drug evaluation service, specialising in models of cardiovascular and inflammatory diseases. Many clients come to WHRL by recommendation, value the quality of the service provided and continue to entrust WHRL with their studies.

WHRL offers a highly differentiated service based on efficiency, reliability and quality. More than 120 disease models and a broad range of techniques are available. Following each study, which frequently is custom-designed to meet the specific needs of our clients, a comprehensive report of the findings is provided, which includes all raw data, statistical analysis and interpretation of the results. This saves valuable time and money for clients, as well as directing them on the most appropriate next steps to develop their compound. WHRL's senior scientists also offer one-to-one discussions and advice on clients' preclinical testing needs. These benefits are not usually available through a conventional CRO.

Academic Fellowships

WHRL works with HCA International Ltd, which funds academic fellowships in biomedical research. These specialist medical trainees recruited by WHRL for academic research, primarily at Queen Mary University of London, additionally provide resident medical officer services to private hospitals in London, representing a considerable investment by the sector in academic biomedical research and high-quality patient care.

Scientific Conferences

WHRL arranges prestigious scientific meetings on recent developments in biomedical research. WHRL has more than 20 years' experience organising national and international scientific conferences, and established in 2006 the annual John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease. This highly successful meeting series attracts over 200 delegates each year from around 25 countries and is accredited with CPD points awarded by the Royal College of Physicians of the UK.

Shareholders

WHRL is a business wholly committed to furthering research into cardiovascular disease, endocrine disorders and inflammation for translational and therapeutic purposes. Its profits are gift aided to its majority shareholder, the William Harvey Research Foundation, which, in turn, awards grants for research in the above disease areas with the aim to facilitate therapeutic innovation and ultimately improve patient outcome and quality of life. Grants amounting to over £10m have been awarded by the WHRF to date. WHRL works primarily, but not exclusively, at the central London facilities of the William Harvey Research Institute at Barts Medical and The London School of Medicine & Dentistry, Queen Mary University of London (which is the minor, but equally important, shareholder of the company).

The Brand

William Harvey Research® is a trademark owned by WHRL. The company also owns the trademarks for William Harvey Conferences®, William Harvey Heart® and William Harvey Consulting® to name but a few.



16-17 March 2018 Royal Society, London, UK

Faculty Chair

Professor Chris Thiemermann, Queen Mary University of London, London, UK

Session Chairs

Paul Corris, Newcastle University, UK

Marc Humbert, Université Paris-Sud, France

Meinhard Kneussl, University of Vienna, Austria

Irene Lang, Medical University of Vienna, Austria

Robert Naeije, Université Libre de Bruxelles, Belgium

Andrew Peacock, University of Glasgow, UK

Marlene Rabinovitch, Stanford University, USA

Olivier Sitbon, Université Paris-Sud, France

Chris Thiemermann, Queen Mary University of London, UK

Dario Vizza, La Sapienza University of Rome, Italy

Brendan Whittle, Queen Mary University of London, UK

Jim White, University of Rochester, USA

Allocated 8 category 1 (external) CPD credits by the Federation of the Royal Colleges of Physicians of the United Kingdom.

www.williamharvey.co.uk



William Harvey Research Limited
John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ
United Kingdom
Tel: +44 (0)20 7882 8808
email: whrl@qmul.ac.uk

 @JVMSseries

 @JVMSseries

 @JVMSseries

Registered in England – Registration No 2437946
Registered office: Charterhouse Square, London EC1M 6BQ

JVMS 2006-2018: Contributor Faculty

Yochai Adir
Amrita Ahluwalia
Stephen L. Archer
Andrew Baker
Robyn Barst
Michael Bauer
Raymond Benza
Robert Bourge
Ghazwan Butrous
Adrian Chester
Lucie Clapp
Gerard Coghlan
John Cooke
Paul Corris
Michele D'Alto
Marion Delcroix
Chris Denton
Laurence Dewachter
Pisana Ferrari
Al Fishman
Rod Flower
Adaani Frost
Sean Gaine
Nazzareno Galie
Francoise Dignat George
Ardeschir Ghoifrani
Adam Giangreco
Simon Gibbs
Wendy Gin-Sing
Mark Gladwin
Mardi Gomborg-Maitland
Mike Grocott
Ekkehard Gruening
Richard Gryglewski
Christophe Guinabert
Sheila G. Haworth
Tim Higenbotam
Adrian Hobbs
Luke Howard
Marc Humbert
Carlos Jardim
Roger Jeffs

Martin Johnson
Shaf Keshavjee
Darrell Kotton
Mordechai Kramer
Meinhard Kneussl
Christopher Lambers
Irene Lang
Peter Lelkes
Marilyne Levy
Vincenzo Libri
James Lordan
Paolo Macchiarini
Mandy MacLean
Hiromi Matsubara
Vallerie McLaughlin
Saul McLaughlin
Sanjay Mehta
Jane Mitchell
Nick Morrell
Edward Morrissey
Helder Mota-Fillipe
Christine Mummery
Monty Mythen
Robert Naeije
John Newman
Laura Niklason
Luke O'Neill
Andrea Olschewski
Mark Ormiston
Harald Ott
Clive Page
Andrew Peacock
Joanna Pepke-Zaba
Dame Julia Polak
Ioana Preston
Soni Pullamsetti
Marlene Rabinovitch
Emma Rawlins
Stuart Rich
Franz Rischard
Stephan Rosenkranz
Nadia Rosenthal

Jenesis Rothblatt
Lewis Rubin
Rajeev Saggarr
Sami Said
John Sanderson
Ralph Schermuly
Karsten Schrör
Bruno Sepodes
Gerald Simonneau
Oliver Sitbon
David Smadja
Thomas Smith
Rogério Souza
Randy Sprague
Duncan Stewart
Ken Suzuki
David Systrom
Nick Talbot
Victor Tapson
Chris Thiemermann
Patrícia Thistlethwaite
Richard Trembath
Jean-Luc Vachiéry
Rebecca Vanderpool
Dario Vizza
Anton Vonk-Noordegraaf
Robert Voswinckel
David Warburton
Tim Warner
Aaron Waxman
Daniel Weiss
Norbert Weissmann
Jim White
Brendan Whittle
Martin Wilkins
Magdi Yacoub
Sir Magdi Yacoub
Mordechai Yigla
Jason Yuan
Dianne Zwicke